The European Chronic Disease Alliance (ECDA)1 welcomes the UN High Level Meeting on Non Communicable Diseases (NCDs) to address the world biggest killers. "It is a memorable day in the history of public health...

Afinitor (evelolimus), a Novartis kidney cancer drug, when combined with hormonal therapy doubled breast cancer patients' progression-free survival, and reduced cancer progression risk by 57% compared to exemestane alone, researchers revealed during a Presidential Symposium at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden...